title: [Local immunotherapy of breast cancer: a case of advanced breast cancer improved by combined local injection therapy with OK-432 and rIL-2].
abstract: An effective immunotherapy for breast cancer has yet to be established. We have recently experienced an inoperable case of advanced breast cancer due to mental disorder. Combined local injection therapy with OK-432 and rIL-2 was performed in addition to non-surgical multi-disciplinary treatment, with obvious therapeutic effects. The case is a 67-year-old female, who had a 5.0 x 4.7 cm tumor in the area A of the left mammary gland. Aspiration cytologic examination revealed class V breast cancer. Besides systemic chemotherapy, local injection therapy with OK-432 2.0 KE on day 1 and rIL-2 500 U on day 3 was performed. Upon starting local injection therapy, a rapid reduction was noted in the tumor diameter (reduction rate, 75.5%). Tumor makers of CEA, CA 15-3 also showed obvious diminution. Although the dose and interval of administration remain to be further examined, the combined local injection therapy with OK-432 and rIL-2 was suggested to be an effective local immunotherapy for breast cancer.
authors.affiliation: Second Dept. of Surgery, Shinsyu University.
authors.forename: M
authors.initials: M
authors.lastname: Fujimori
authors.forename: A
authors.initials: A
authors.lastname: Sugenoya
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: H
authors.initials: H
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Komatsu
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Shimizu
authors.forename: S
authors.initials: S
authors.lastname: Tsuchiya
authors.forename: F
authors.initials: F
authors.lastname: Iida
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000097:blood / Q000473:pathology / Q000628:therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007267:Injections / Q000379:methods; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000627:therapeutic use; D010844:Picibanil / Q000008:administration & dosage* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction
chemical_list: D001688:Biological Products; D014408:Biomarkers, Tumor; D007376:Interleukin-2; D011994:Recombinant Proteins; D010844:Picibanil